DA, it's not snake oil any more than Cold-eeze is. Although there's been some trouble replicating the Cleveland Clinic's original study, I don't think there's much question that, in theory anyway, zinc can mechanically interfere with the virus attaching itself to the nasal membranes. (Howard and other medical types, forgive me if I'm being too simplistic or cavalier about whether it's a given.) Cold-eeze lozenges do a number on my stomach, but I have very bad colds when I don't use it, and very minor symptoms and shorter cold durations when I do, so I know it works. And that's with zinc that has to make its way to the nasal receptors through the bloodstream. Here, you're physically blocking the receptor site with the stuff. Also, am I making this up, medical types, or didn't I read recently (pre-Zicam) that Vaseline dabbed in the nose was found to cut down the incidence of colds in a study? Same idea- it creates a wall between the membrane surface and the nasty little beasties that are flying around, or that crawl in from your hands when you touch your face. Next, they should come out with Zicam eye drops because colds can be transmitted hand-to-eye, too <g>.
As others are saying, how can this NOT be a $30-$50 stock?! I'm going to check the historical daily charts for Quigley when it first came out with Cold-eeze, because I don't think their run-up (from single digits to the 30's, if I remember, and that was for an unknown OTC-BB stock that institutions didn't trust and/or couldn't buy!!) was instantaneous, either.
Finally, technicians and others, for Pete's sake look at the 2-month chart. When a stock runs from 6 to 15, and you combine the normal "sell on the news" inclination with a less than stellar company press release, and with the shorts frantically sticking their fingers and all other available body parts in the dike, no wonder you get a pullback. But if the best they could do was squash it down a point or two, intraday, while there was NO newspaper, magazine or TV coverage of a great story (don't forget February is a ratings "sweeps month" when TV stations love to run interesting special segments on news shows)... suffice it to say that my confidence has been barely bruised.
Oh yeah, one more thing. I straightened out the mystery of why yesterday's press release didn't appear where it should've. I had looked for it on Bloomberg, but GelTech apparently submitted it to PR Newswire classified under "Health" but not under GumTech by company, and they didn't put "(NASDAQ: GUMM)" in the body of the release, so it didn't get filed under "Company News" for GUMM on Bloomberg. I called Bloomberg's research dept. this morning, had the guy search PRN stories until he found GelTech's, and he then classified it so it now comes up on Bloomberg when someone looks under GUMM's news stories. But someone would probably have to do that (or similar) with Yahoo, Bridge, Reuters, etc., in order for the story to be accessible under "GUMM" on those services. Dow Jones probably wouldn't have run their own summary anyway since there was no financial data in the release, and they often steer clear of product launch announcements.
FWIW (admittedly not much), I see a small (maybe 1/4 point) gap up tomorrow, after which the shorts will give it a whack. After that, who knows, but I'm holding for the inevitable media coverage. |
